Strong Selection Significantly Increases Epistatic Interactions in the Long-Term Evolution of a Protein

PLoS Genetics

Volumn 12, Issue 3, 2016, Pages

  Gupta, Aditi ^a,b,c   Adami, Christoph ^a,b  

^a Michigan State University ^*  (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ADAPTATION; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; ENZYME ANALYSIS; EPISTASIS; GENETIC SELECTION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; MOLECULAR EVOLUTION; NONHUMAN; PHYSICAL CHEMISTRY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION;

ADAPTATION, PHYSIOLOGICAL; EPISTASIS, GENETIC; EVOLUTION, MOLECULAR; HIV PROTEASE; HIV-1; HUMANS; MUTATION; SELECTION, GENETIC;

EID: 84962469602     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1005960     Document Type: Article

References (91)

1. de Visser JAGM, Cooper TF, Elena SF, The causes of epistasis. Proc Roy Soc B. 2011;278:3617–24. doi: 10.1098/rspb.2011.1537
2. Ortlund EA, Bridgham JT, Redinbo MR, Thornton JW, Crystal structure of an ancient protein: evolution by conformational epistasis. Science. 2007;317:1544–8. doi: 10.1126/science.114281917702911
3. Tokuriki N, Stricher F, Serrano L, Tawfik DS, How protein stability and new functions trade off. PLoS Comput Biol. 2008;4:e1000002. doi: 10.1371/journal.pcbi.100000218463696
4. Soskine M, Tawfik DS, Mutational effects and the evolution of new protein functions. Nat Rev Genet. 2010;11:572–82. doi: 10.1038/nrg280820634811
5. Bershtein S, Segal M, Bekerman R, Tokuriki N, Tawfik DS, Robustness-epistasis link shapes the fitness landscape of a randomly drifting protein. Nature. 2006;444:929–32. doi: 10.1038/nature0538517122770
6. Bank C, Hietpas RT, Jensen JD, Bolon DNA, A systematic survey of an intragenic epistatic landscape. Mol Biol Evol. 2015;32:229–38. doi: 10.1093/molbev/msu30125371431
7. Hayden EJ, Wagner A, Environmental change exposes beneficial epistatic interactions in a catalytic RNA. Proc Roy Soc B. 2012;279:3418–25. doi: 10.1098/rspb.2012.0956
8. Maisnier-Patin S, Andersson DI, Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res Microbiol. 2004;155:360–9. doi: 10.1016/j.resmic.2004.01.01915207868
9. Flynn KM, Cooper TF, Moore FBG, Cooper VS, The environment affects epistatic interactions to alter the topology of an empirical fitness landscape. PLoS Genet. 2013;9:e1003426. doi: 10.1371/journal.pgen.100342623593024
10. Martinez-Picado J, Martínez MA, HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res. 2008;134:104–23. doi: 10.1016/j.virusres.2007.12.02118289713
11. Bloom JD, Silberg JJ, Wilke CO, Drummond DA, Adami C, Arnold FH, Thermodynamic prediction of protein neutrality. Proc Natl Acad Sci USA. 2005;102:606–611. doi: 10.1073/pnas.040674410215644440
12. Chang MW, Torbett BE, Accessory mutations maintain stability in drug-resistant HIV-1 protease. J Mol Biol. 2011;410:756–760. doi: 10.1016/j.jmb.2011.03.03821762813
13. Araya CL, Fowler DM, Chen W, Muniez I, Kelly JW, Fields S, A fundamental protein property, thermodynamic stability, revealed solely from large-scale measurements of protein function. Proc Natl Acad Sci U S A. 2012;109:16858–63. doi: 10.1073/pnas.120975110923035249
14. Trindade S, Sousa A, Xavier KB, Dionisio F, Ferreira MG, Gordo I, Positive epistasis drives the acquisition of multidrug resistance. PLoS Genet. 2009;5:e1000578. doi: 10.1371/journal.pgen.100057819629166
15. Harms MJ, Thornton JW, Historical contingency and its biophysical basis in glucocorticoid receptor evolution. Nature. 2014;512:203–7. doi: 10.1038/nature1341024930765
16. Wellner A, Raitses Gurevich M, Tawfik DS, Mechanisms of protein sequence divergence and incompatibility. PLoS Genet. 2013;9:e1003665. doi: 10.1371/journal.pgen.100366523935519
17. Lunzer M, Golding GB, Dean AM, Pervasive cryptic epistasis in molecular evolution. PLoS Genet. 2010;6:e1001162. doi: 10.1371/journal.pgen.100116220975933
18. Lozovsky ER, Chookajorn T, Brown KM, Imwong M, Shaw PJ, Kamchonwongpaisan S, et al. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci U S A. 2009;106:12025–30. doi: 10.1073/pnas.090592210619587242
19. Borrell S, Teo Y, Giardina F, Streicher EM, Klopper M, Feldmann J, et al. Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis. Evol Med Public Health. 2013;2013:65–74. doi: 10.1093/emph/eot00324481187
20. Lagator M, Colegrave N, Neve P, Selection history and epistatic interactions impact dynamics of adaptation to novel environmental stresses. Proc Roy Soc B. 2014;281:20141679. doi: 10.1098/rspb.2014.1679
21. Gong LI, Bloom JD, Epistatically interacting substitutions are enriched during adaptive protein evolution. PLoS Genet. 2014;10:e1004328. doi: 10.1371/journal.pgen.100432824811236
22. Kouyos RD, Silander OK, Bonhoeffer S, Epistasis between deleterious mutations and the evolution of recombination. Trends Ecol Evol. 2007;22:308–15. doi: 10.1016/j.tree.2007.02.01417337087
23. Kouyos RD, Leventhal GE, Hinkley T, Haddad M, Whitcomb JM, Petropoulos CJ, et al. Exploring the complexity of the HIV-1 fitness landscape. PLoS Genet. 2012;8:e1002551. doi: 10.1371/journal.pgen.100255122412384
24. Hinkley T, Martins J, Chappey C, Haddad M, Stawiski E, Whitcomb JM, et al. A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat Genet. 2011;43:487–9. doi: 10.1038/ng.79521441930
25. Ostman B, Hintze A, Adami C, Impact of epistasis and pleiotropy on evolutionary adaptation. Proc Royal Soc B. 2012;279:247–56. doi: 10.1098/rspb.2011.0870
26. Kryazhimskiy S, Rice DP, Jerison ER, Desai MM, Global epistasis makes adaptation predictable despite sequence-level stochasticity. Science. 2014;344:1519–22. doi: 10.1126/science.125093924970088
27. Szamecz B, Boross G, Kalapis D, Kovács K, Fekete G, Farkas Z, et al. The genomic landscape of compensatory evolution. PLoS Biol. 2014;12:e1001935. doi: 10.1371/journal.pbio.100193525157590
28. Quandt EM, Deatherage DE, Ellington AD, Georgiou G, Barrick JE, Recursive genomewide recombination and sequencing reveals a key refinement step in the evolution of a metabolic innovation in Escherichia coli. Proc Natl Acad Sci U S A. 2014;111:2217–22. doi: 10.1073/pnas.131456111124379390
29. Brik A, Wong CH, HIV-1 protease: Mechanism and drug discovery. Org Biomol Chem. 2003;1:5–14. doi: 10.1039/b208248a12929379
30. Mansky LM, Temin HM, Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995;69:5087–94. 7541846
31. Brown AJ, Korber BT, Condra JH, Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy. AIDS Res Hum Retroviruses. 1999;15:247–253. doi: 10.1089/08892229931142010052755
32. Hoffman NG, Schiffer CA, Swanstrom R, Covariation of amino acid positions in HIV-1 protease. Virology. 2003;314:536–548. doi: 10.1016/S0042-6822(03)00484-714554082
33. Haq O, Levy RM, Morozov AV, Andrec M, Pairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease. BMC Bioinformatics. 2009;10Suppl 8:S10. doi: 10.1186/1471-2105-10-S8-S1019758465
34. Coffin JM, HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483–9. doi: 10.1126/science.78249477824947
35. Pennings PS, Standing genetic variation and the evolution of drug resistance in HIV. PLoS Comput Biol. 2012;8:e1002527. doi: 10.1371/journal.pcbi.100252722685388
36. Mammano F, Petit C, Clavel F, Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol. 1998;72:7632–7637. 9696866
37. Pennings PS, Kryazhimskiy S, Wakeley J, Loss and recovery of genetic diversity in adapting populations of HIV. PLoS Genet. 2014;10:e1004000. doi: 10.1371/journal.pgen.100400024465214
38. Morand-Joubert L, Charpentier C, Poizat G, Chêne G, Dam E, Raguin G, et al. Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy. Antivir Ther. 2006;11:143–54. 16640095
39. Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver DA, Albert J, et al. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. Retrovirology. 2012;9:81. doi: 10.1186/1742-4690-9-8123031662
40. Taverna DM, Goldstein RA, Why are proteins marginally stable?Proteins. 2002;46:105–9. 11746707
41. Bloom JD, Arnold FH, In the light of directed evolution: pathways of adaptive protein evolution. Proc Natl Acad Sci U S A. 2009;106Suppl 1:9995–10000. doi: 10.1073/pnas.090152210619528653
42. Burch CL, Chao L, Evolution by small steps and rugged landscapes in the RNA virus ϕ6. Genetics. 1999;151:921–7. 10049911
43. Kvitek DJ, Sherlock G, Reciprocal sign epistasis between frequently experimentally evolved adaptive mutations causes a rugged fitness landscape. PLoS Genet. 2011;7:e1002056. doi: 10.1371/journal.pgen.100205621552329
44. Adami C, Information theory in molecular biology. Phys Life Rev. 2004;1:3–22. doi: 10.1016/j.plrev.2004.01.002
45. Strelioff CC, Lenski RE, Ofria C, Evolutionary dynamics, epistatic interactions, and biological information. J Theor Biol. 2010;266:584–94. doi: 10.1016/j.jtbi.2010.07.02520659477
46. Anastassiou D, Computational analysis of the synergy among multiple interacting genes. Mol Syst Biol. 2007;3:83. doi: 10.1038/msb410012417299419
47. da Silva J, Amino acid covariation in a functionally important human immunodeficiency virus type 1 protein region is associated with population subdivision. Genetics. 2009;182:265–75. doi: 10.1534/genetics.108.099853
48. Wang Q, Lee C, Distinguishing functional amino acid covariation from background linkage disequilibrium in HIV protease and reverse transcriptase. PLoS One. 2007;2:e814. doi: 10.1371/journal.pone.000081417726544
49. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007;21:215–23. doi: 10.1097/QAD.0b013e328011e69117197813
50. Jakobsen MR, Tolstrup M, Søgaard OS, Jørgensen LB, Gorry PR, Laursen A, et al. Transmission of HIV-1 drug-resistant variants: Prevalence and effect on treatment outcome. Clin Infect Dis. 2010;50:566–573. doi: 10.1086/65000120085464
51. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L, Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet. 1999;354:729–733. doi: 10.1016/S0140-6736(98)12262-610475184
52. Shafer RW, Schapiro JM, HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev. 2008;10:67–84. 18615118
53. Mammano F, Trouplin V, Zennou V, Clavel F, Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug. J Virol. 2000;74:8524–8531. doi: 10.1128/JVI.74.18.8524-8531.200010954553
54. Sokalingam S, Raghunathan G, Soundrarajan N, Lee SG, A study on the effect of surface lysine to arginine mutagenesis on protein stability and structure using green fluorescent protein. PLoS One. 2012;7:e40410. doi: 10.1371/journal.pone.004041022792305
55. Martinez-Picado J, Savara AV, Sutton L, D’Aquila RT, Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol. 1999;73:3744–52. 10196268
56. Carothers JM, Oestreich SC, Davis JH, Szostak JW, Informational complexity and functional activity of RNA structures. J American Chem Society. 2004;126:5130–5137. doi: 10.1021/ja031504a
57. Baxter JD, Schapiro JM, Boucher CAB, Kohlbrenner VM, Hall DB, Scherer JR, et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol. 2006;80:10794–10801. doi: 10.1128/JVI.00712-0616928764
58. Socolich M, Lockless SW, Russ WP, Lee H, Gardner KH, Ranganathan R, Evolutionary information for specifying a protein fold. Nature. 2005;437:512–8. doi: 10.1038/nature0399116177782
59. Weinreich DM, Lan Y, Wylie CS, Heckendorn RB, Should evolutionary geneticists worry about higher-order epistasis?Curr Opin Genet Dev. 2013;23:700–707. doi: 10.1016/j.gde.2013.10.00724290990
60. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–12. doi: 10.1002/jcc.2008415264254
61. Elena SF, Lenski RE, Evolution experiments with microorganisms: The dynamics and genetic bases of adaptation. Nat Rev Genet. 2003;4:457–69. doi: 10.1038/nrg108812776215
62. Barrick JE, Yu DS, Yoon SH, Jeong H, Oh TK, Schneider D, et al. Genome evolution and adaptation in a long-term experiment with Escherichia coli. Nature. 2009;461:1243–7. doi: 10.1038/nature0848019838166
63. Poelwijk FJ, Kiviet DJ, Weinreich DM, Tans SJ, Empirical fitness landscapes reveal accessible evolutionary paths. Nature. 2007;445:383–6. doi: 10.1038/nature0545117251971
64. Loeb DD, Swanstrom R, Everitt L, Manchester M, Stamper SE, Hutchison CA, 3rdComplete mutagenesis of the HIV-1 protease. Nature. 1989;340:397–400. doi: 10.1038/340397a02666861
65. Velazquez-Campoy A, Muzammil S, Ohtaka H, Schön A, Vega S, Freire E, Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: Implications for inhibitor design. Curr Drug Targets Infect Disord. 2003;3:311–328. doi: 10.2174/156800503348105114754432
66. Louis JM, Tözsér J, Roche J, Matúz K, Aniana A, Sayer JM, Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease. Biochemistry. 2013;52:7678–7688. doi: 10.1021/bi400962r24079831
67. Muzammil S, Ross P, Freire E, A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry. 2003;42:631–638. doi: 10.1021/bi027019u12534275
68. Agniswamy J, Shen CH, Aniana A, Sayer JM, Louis JM, Weber IT, HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements. Biochemistry. 2012;51:2819–2828. doi: 10.1021/bi201831722404139
69. Kauffman SA, Weinberger ED, The NK model of rugged fitness landscapes and its application to maturation of the immune response. J Theor Biol. 1989;141:211–45. doi: 10.1016/S0022-5193(89)80019-02632988
70. Franke J, Klözer A, de Visser JAGM, Krug J, Evolutionary accessibility of mutational pathways. PLoS Comput Biol. 2011;7:e1002134. doi: 10.1371/journal.pcbi.100213421876664
71. Draghi JA, Plotkin JB, Selection biases the prevalence and type of epistasis along adaptive trajectories. Evolution. 2013;67:3120–31. doi: 10.1111/evo.1219224151997
72. Nahum JR, Godfrey-Smith P, Harding BN, Marcus JH, Carlson-Stevermer J, Kerr B, A tortoise-hare pattern seen in adapting structured and unstructured populations suggests a rugged fitness landscape in bacteria. Proc Natl Acad Sci U S A. 2015;112:7530–5. doi: 10.1073/pnas.141063111225964348
73. Khan AI, Dinh DM, Schneider D, Lenski RE, Cooper TF, Negative epistasis between beneficial mutations in an evolving bacterial population. Science. 2011;332:1193–6. doi: 10.1126/science.120380121636772
74. Chou HH, Chiu HC, Delaney NF, Segrè D, Marx CJ, Diminishing returns epistasis among beneficial mutations decelerates adaptation. Science. 2011;332:1190–2. doi: 10.1126/science.120379921636771
75. Tokuriki N, Jackson CJ, Afriat-Jurnou L, Wyganowski KT, Tang R, Tawfik DS, Diminishing returns and tradeoffs constrain the laboratory optimization of an enzyme. Nat Commun. 2012;3:1257. doi: 10.1038/ncomms224623212386
76. Wilke CO, Lenski RE, Adami C, Compensatory mutations cause excess of antagonistic epistasis in RNA secondary structure folding. BMC Evol Biol. 2003Feb;3:3. doi: 10.1186/1471-2148-3-312590655
77. Phillips PC, Epistasis–the essential role of gene interactions in the structure and evolution of genetic systems. Nat Rev Genet. 2008;9:855–67. doi: 10.1038/nrg245218852697
78. Carter AJR, Hermisson J, Hansen TF, The role of epistatic gene interactions in the response to selection and the evolution of evolvability. Theor Popul Biol. 2005;68:179–96. doi: 10.1016/j.tpb.2005.05.00216122771
79. Chiotti KE, Kvitek DJ, Schmidt KH, Koniges G, Schwartz K, Donckels EA, et al. The Valley-of-Death: Reciprocal sign epistasis constrains adaptive trajectories in a constant, nutrient limiting environment. Genomics. 2014;104:431–7. doi: 10.1016/j.ygeno.2014.10.01125449178
80. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ, Evidence for positive epistasis in HIV-1. Science. 2004;306:1547–50. doi: 10.1126/science.110178615567861
81. Arts EJ, Commentary on the role of treatment-related HIV compensatory mutations on increasing virulence: New discoveries twenty years since the clinical testing of protease inhibitors to block HIV-1 replication. BMC Med. 2012;10:114. doi: 10.1186/1741-7015-10-11423031614
82. Karasov T, Messer PW, Petrov DA, Evidence that adaptation in Drosophila is not limited by mutation at single sites. PLoS Genet. 2010;6:e1000924. doi: 10.1371/journal.pgen.100092420585551
83. Ross L, Lim ML, Liao Q, Wine B, Rodriguez AE, Weinberg W, et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities. HIV Clin Trials. 2007;8:1–8. doi: 10.1310/hct0801-117434843
84. Wang D, Hicks CB, Goswami ND, Tafoya E, Ribeiro RM, Cai F, et al. Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. J Virol. 2011;85:6403–15. doi: 10.1128/JVI.02389-1021490094
85. Adami C, Cerf NJ, Physical complexity of symbolic sequences. Physica D. 2000;137:62–69. doi: 10.1016/S0167-2789(99)00179-7
86. Adami C, The use of information theory in evolutionary biology. Ann NY Acad Sci. 2012;1256:49–65. doi: 10.1111/j.1749-6632.2011.06422.x22320231
87. Rivoire O, Leibler S, The value of information for populations in varying environments. J Stat Phys. 2011;142:1124–1166. doi: 10.1007/s10955-011-0166-2
88. Fano RM, Transmission of Information. New York and London: MIT Press and John Wiley & Sons; 1961.
89. Basharin GP, On a statistical estimate for the entropy of a sequence of independent random variables. Theory Probability Applic. 1959;4:333–337. doi: 10.1137/1104033
90. Nemenman I, Shafee F, Bialek W. Entropy and Inference, revisited. In: Adv Neural Inf Process Syst. vol. 14; 2002. p. 471–478.
91. R Core TeamR: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.